HB1801
As of the edition of 20 October 2026, HB1801 is a drug known only by a code name: in active development; acts on TUBA1A, TUBA1B and TUBA1C and 12 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 10, 0 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| TUBB4A | Tubulin beta-4A chain | P04350 |
| TUBB | Tubulin beta chain | P07437 |
| TUBA3C | Tubulin alpha-3C chain | P0DPH7 |
| TUBA1B | Tubulin alpha-1B chain | P68363 |
| TUBA4A | Tubulin alpha-4A chain | P68366 |
| TUBB4B | Tubulin beta-4B chain | P68371 |
| TUBB3 | Tubulin beta-3 chain | Q13509 |
| TUBB2A | Tubulin beta-2A chain | Q13885 |
| TUBB8 | Tubulin beta-8 chain | Q3ZCM7 |
| TUBA3E | Tubulin alpha-3E chain | Q6PEY2 |
| TUBA1A | Tubulin alpha-1A chain | Q71U36 |
| TUBA1C | Tubulin alpha-1C chain | Q9BQE3 |
| TUBB6 | Tubulin beta-6 chain | Q9BUF5 |
| TUBB2B | Tubulin beta-2B chain | Q9BVA1 |
| TUBB1 | Tubulin beta-1 chain | Q9H4B7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 5 | 0 | 4 | 0 |
| Phase 3 | 5 | 0 | 5 | 0 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cspc | Lead sponsor of trials | 2023 to now |
| Shanghai JMT-Bio | Lead sponsor of trials | 2023 to now |